Reviewing Masimo Corporation (MASI) and Entellus Medical (ENTL)
Masimo Corporation (NASDAQ: MASI) and Entellus Medical (NASDAQ:ENTL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Valuation & Earnings
This table compares Masimo Corporation and Entellus Medical’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Masimo Corporation||$730.06 million||6.21||$182.11 million||$6.14||14.21|
|Entellus Medical||$80.80 million||5.43||-$26.99 million||($1.66)||-10.41|
Masimo Corporation has higher revenue and earnings than Entellus Medical. Entellus Medical is trading at a lower price-to-earnings ratio than Masimo Corporation, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Masimo Corporation has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Entellus Medical has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
Institutional and Insider Ownership
84.1% of Masimo Corporation shares are owned by institutional investors. Comparatively, 67.6% of Entellus Medical shares are owned by institutional investors. 16.6% of Masimo Corporation shares are owned by company insiders. Comparatively, 9.1% of Entellus Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Masimo Corporation and Entellus Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Masimo Corporation and Entellus Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Masimo Corporation currently has a consensus target price of $97.00, indicating a potential upside of 11.17%. Entellus Medical has a consensus target price of $22.00, indicating a potential upside of 27.31%. Given Entellus Medical’s higher possible upside, analysts plainly believe Entellus Medical is more favorable than Masimo Corporation.
Masimo Corporation beats Entellus Medical on 11 of the 12 factors compared between the two stocks.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Entellus Medical Company Profile
Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company’s XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.
Receive News & Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related companies with MarketBeat.com's FREE daily email newsletter.